PD 149163Alternative Names: PD149163
Latest Information Update: 23 Jul 2002
At a glance
- Originator Pfizer
- Class Antipsychotics
- Mechanism of Action Neurotensin receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 21 Jun 2000 Warner-Lambert has merged with Pfizer
- 03 Mar 1999 New profile
- 03 Mar 1999 Preclinical development for Schizophrenia in USA (Unknown route)